Inhibition of innate immune responses to tumours by CD4+CD25+ regulatory T cells [Abstract]

Richards, H. E., Simon, A. K., Jones, E., Williams, Anwen Sian ORCID: https://orcid.org/0000-0001-6118-020X, Screaton, G. R. and Gallimore, Awen Myfanwy ORCID: https://orcid.org/0000-0001-6675-7004 2005. Inhibition of innate immune responses to tumours by CD4+CD25+ regulatory T cells [Abstract]. Immunology 116 (s1) , p. 36. 10.1111/j.1365-2567.2005.02287.x

Full text not available from this repository.

Abstract

CD4+ CD25+ regulatory T cells (Treg) have been shown to suppress tumour-specific T cell responses both in vitro and in vivo. Using a model of tumour rejection involving a melanoma cell line expressing Fas ligand (B16FasL), which can be rejected by innate immune responses, we show that Treg inhibit these responses, thereby promoting tumour growth. Adoptive transfer of Treg into RAG-/- mice inhibited tumour rejection and in vivo depletion of Treg in wild-type mice enhanced tumour rejection. An in-depth analysis of the immune response leading to tumour rejection has highlighted an important role for neutrophils, NK cells and macrophages. We are currently investigating whether 1) Treg directly inhibit the activity of these cells or 2) Treg suppress the activity of multiple cell-types indirectly via inhibition of Dendritic Cell activity. Delineating these pathways will further our understanding of how the immune system can be manipulated to enhance tumour rejection.

Item Type:	Article
Date Type:	Publication
Status:	Published
Schools:	Medicine Systems Immunity Research Institute (SIURI)
Subjects:	Q Science > QR Microbiology > QR180 Immunology
Publisher:	Wiley-Blackwell
ISSN:	1365-2567
Last Modified:	24 Oct 2022 10:13
URI:	https://orca.cardiff.ac.uk/id/eprint/43466

Actions (repository staff only)

Edit Item